PA
Parul Agarwal
University of Pennsylvania, Johns Hopkins University, Hospital of the University of Pennsylvania, Boston University School of Medicine
0000-0001-9549-5023
Employment
-
University of Pennsylvania Assistant Professor2022 - Present
Education
-
Johns Hopkins University Hematology/Oncology Fellow2019 - 2022
-
Hospital of the University of Pennsylvania Internal Medicine Resident2015 - 2018
-
Boston University School of Medicine MD2011 - 2015
-
Boston University2008 - 2011
Projects & Funding
Projects & funding information is unavailable.
Publications (47)
- Supplementary Table 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Save
- Supplementary Table 2 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Save
- Supplementary Table 3 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Save
- Data from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Save
- Supplementary Figure 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Save
- Supplementary Tables 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Save
- Supplementary Figure 1 from Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors Save
- Supplementary Figure 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Save
- Supplementary Tables 1 from A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Save
- A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma Save